Literature DB >> 29136502

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.

Joshua J Meeks1, Seth P Lerner2.   

Abstract

In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29136502     DOI： 10.1016/j.ccell.2017.08.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  6 in total

1.  Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.

Authors:  Robert S Svatek; Niannian Ji; Essel de Leon; Neelam Z Mukherjee; Aashish Kabra; Vincent Hurez; Marlo Nicolas; Joel E Michalek; Martin Javors; Karen Wheeler; Z Dave Sharp; Carolina B Livi; Zhen-Ju Shu; David Henkes; Tyler J Curiel
Journal:  Cancer Immunol Res       Date:  2018-12-18       Impact factor: 11.151

2.  Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Authors:  Vadim S Koshkin; Jorge A Garcia; Jordan Reynolds; Paul Elson; Cristina Magi-Galluzzi; Jesse K McKenney; Kumiko Isse; Evan Bishop; Laura R Saunders; Aysegul Balyimez; Summya Rashid; Ming Hu; Andrew J Stephenson; Amr F Fergany; Byron H Lee; Georges-Pascal Haber; Afshin Dowlati; Timothy Gilligan; Moshe C Ornstein; Brian I Rini; Mohamed E Abazeed; Omar Y Mian; Petros Grivas
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

3.  Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions.

Authors:  John L Pfail; Andrew B Katims; Parissa Alerasool; John P Sfakianos
Journal:  World J Urol       Date:  2020-10-15       Impact factor: 4.226

4.  High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.

Authors:  Guoliang Wang; Yi Huang; Feilong Yang; Xiaojun Tian; Kun Wang; Li Liu; Yidong Fan; Xiaofeng Li; Luchao Li; Benkang Shi; Yichang Hao; Chuanyou Xia; Qingsheng Nie; Yue Xin; Zhenfeng Shi; Lulin Ma; Dawei Xu; Cheng Liu
Journal:  Aging (Albany NY)       Date:  2020-02-01       Impact factor: 5.682

5.  tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5'-tRF-LysCTT Results in Disease Early Progression and Patients' Poor Treatment Outcome.

Authors:  Maria-Alexandra Papadimitriou; Margaritis Avgeris; Panagiotis Levis; Evangelia Ch Papasotiriou; Georgios Kotronopoulos; Konstantinos Stravodimos; Andreas Scorilas
Journal:  Cancers (Basel)       Date:  2020-12-06       Impact factor: 6.639

Review 6.  Immune status for monitoring and treatment of bladder cancer.

Authors:  Shen Pan; Shijie Li; Yunhong Zhan; Xiaonan Chen; Ming Sun; Xuefeng Liu; Bin Wu; Zhenhua Li; Bitian Liu
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.